News | Blood Testing | September 04, 2018

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

Prevencio’s multi-protein, AI-driven HART PAD biomarker test has potential to improve clinical outcomes and reduce costs in the treatment of diabetic patients

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient

September 4, 2018 — Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June demonstrating Prevencio’s HART CAD and HART CVE tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in DM patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.

In this study, researchers assessed the company’s artificial intelligence (AI)-driven HART PAD diagnostic test on patients enrolled in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study. The HART PAD test algorithmically assesses six biomarkers linked to atherosclerosis, as well as a patient’s history of hypertension. In patients with DM, the HART PAD panel had excellent performance for diagnosis of PAD. Using a five-point score, a score of 1 had a 100 percent negative predictive value (NPV) and a score of 5 had a 95 percent positive predictive value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularization in patients with PAD. These results were comparable to those patients without DM.

Principal investigator James L. Januzzi, M.D., practicing cardiologist at MGH and professor of medicine at Harvard Medical School, said, “The HART PAD test may allow for the diagnosis and treatment of many more patients with currently undetected PAD. In the clinical setting, these findings could assist physicians to identify peripheral artery disease earlier, provide guideline-recommended care and monitor at-risk patients for vascular complications. We believe HART tests could also play an important role in identifying high-risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”

PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with DM are at substantial risk of developing PAD. Patients with PAD have increased risk of CAD, heart attack or stroke and, if left untreated, PAD can lead to foot or leg amputation.

For more information: www.prevenciomed.com

Related Content

vRad Presents AI Model to Assess Probability of Aortic Dissection
News | Artificial Intelligence | July 01, 2019
vRad (Virtual Radiologic), a Mednax company recently made a scientific presentation, “Screening for Aortic Dissection...
Videos | Artificial Intelligence | June 28, 2019
This is a quick example of how artificial intelligence (AI) is being integrated on the back end of cardiac ultrasound
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
FDA Clears Aidoc's AI Solution for Flagging Pulmonary Embolism
Technology | Artificial Intelligence | May 15, 2019
Artificial intelligence (AI) solutions provider Aidoc has been granted U.S. Food and Drug Administration (FDA)...
Basic artificial intelligence is already incorporated into several premium echocardiography systems. This example is from the Philips Epiq, which can take 3-D datasets and the AI automatically identifies and segments the cardiac anatomy. It then extracts the best images for each of the standard views for an echocardiogram to eliminate variation between operators. The next generation echo AI software will pull in data from the electronic medical records and imaging data to offer suggested diagnoses.

Basic artificial intelligence is already incorporated into several premium echocardiography systems. This example is from the Philips Epiq, where the AI takes 3-D datasets and automatically identifies and segments the cardiac anatomy. It then extracts the best images for each of the standard echocardiogram views to eliminate variation between operators. The next generation echo AI software will pull in data from the electronic medical records and imaging data to offer suggested diagnoses.

Feature | Artificial Intelligence | May 07, 2019 | Ross Upton
Artificial Intelligence has a multitude of impacts on our daily lives, from recommending movies based upon your Netfl
Overlay Init